What to Read Next on Medscape
Special Coverage: COVID-19
Latest
Perspective
Guidelines
Drugs & Diseases
Global Coverage
Additional Resources
Business of Medicine
ObesityWeek® 2022: What’s Stopping Effective Treatment of Obesity?
More Than Half of the World Will Be Overweight or Obese by 2035: Report
Weighing Childhood Obesity Interventions
Recommended Reading
newsSocial Needs Case Management Cuts Acute Care UsageEU Investigates Ozempic, Weight-Loss Drug Saxenda After Suicidal Thoughts ReportedNov 17, 2023 This Week in Cardiology PodcastnewsWill Imaging Improve Migraine Diagnosis and Management?
Related Conditions & Procedures
Obesity in Children
Prenatal Diagnosis and Fetal Therapy
Thigh and Knee Liposuction
Heart Transplantation
Cesarean Delivery
Pediatric Lipid Disorders in Clinical Practice
SLIDESHOW
9 Causes of Discolored Urine
Expert Commentary
Link Between Vitamin D Deficiency and Obesity Unclear
Key Updates in Obesity From AHA 2023
Semaglutide Reduces Cardiovascular Risk in Obesity Without Diabetes
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/prescribing-glp-1-agonists-2023a1000urx

















![[News] Japan Develops 10nm Nanoimprint Technology, with Potential to Tackle EUV Bottleneck – TrendForce](https://earth-news.info/wp-content/uploads/2025/12/329851-news-japan-develops-10nm-nanoimprint-technology-with-potential-to-tackle-euv-bottleneck-trendforce-360x180.jpg)










